Literature DB >> 10329824

Differential B- and T-cell activation in Wegener's granulomatosis.

E R Popa1, C A Stegeman, N A Bos, C G Kallenberg, J W Tervaert.   

Abstract

BACKGROUND: Autoimmune mechanisms are postulated to play a role in the development and progression of Wegener's granulomatosis (WG), a form of systemic, idiopathic necrotizing vasculitis.
OBJECTIVE: We investigated the relation between lymphocyte activation and disease activity in patients with WG.
METHODS: B- and T-lymphocyte activation was studied by cytometric assessment of the expression of the activation markers CD38 on B cells and CD25 and HLA-DR on CD4(+) and CD8(+) T-cell subsets, respectively. Activation at the cellular level was related to serum levels of antineutrophil cytoplasmic antibodies and soluble IL-2 receptor, which can be regarded as soluble activation markers of B and T cells.
RESULTS: Percentages of CD38(bright) activated B cells were higher in patients with active WG than in patients experiencing disease remission (P <.05) or in healthy control subjects (P <.05). Percentages of activated CD4(+) and CD8(+) T cells were higher in patients with active WG (CD4 subset, P <.0001; CD8 subset, P <.005) than in healthy individuals. An increased percentage of activated T cells of both subsets was also seen in patients whose condition was in remission, as compared with healthy control subjects (CD4 subset, P <.0005; CD8 subset, P <. 001). Lymphocyte activation at the cellular level did not correlate with plasma levels of antineutrophil cytoplasmic antibodies or soluble IL-2 receptor.
CONCLUSION: In WG, B-cell activation is related to active disease, whereas T-cell activation persists during remission of the disease, which points to an intrinsic disordered immune system in this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329824     DOI: 10.1016/s0091-6749(99)70434-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  53 in total

Review 1.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  ANCA-associated vasculitides-lessons from the adult literature.

Authors:  Joannis Vamvakopoulos; Caroline O Savage; Lorraine Harper
Journal:  Pediatr Nephrol       Date:  2010-04-01       Impact factor: 3.714

3.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 4.  Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Jeremy M Clain; Rodrigo Cartin-Ceba; Fernando C Fervenza; Ulrich Specks
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

Review 5.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 6.  Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

Authors:  O Flossmann; R B Jones; D R W Jayne; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

7.  Polymorphisms in PDCD1 gene are not associated with Wegener's granulomatosis.

Authors:  Priya Sakthivel; Ricardo Giscombe; Ryan Ramanujam; Ann Kari Lefvert
Journal:  Rheumatol Int       Date:  2009-05-18       Impact factor: 2.631

Review 8.  Biomarkers in ANCA-associated vasculitis.

Authors:  Lindsay Lally; Robert F Spiera
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

9.  Analysis of T-cell receptor usage in myeloperoxidase--antineutrophil cytoplasmic antibody-associated renal vasculitis.

Authors:  Kouichi Hirayama; Takashi Ishizu; Homare Shimohata; Yasunori Miyamoto; Tomoko Kakita; Miho Nagai; Yujiro Ogawa; Shogo Fujita; Aki Hirayama; Kunihiro Yamagata; Masaki Kobayashi; Akio Koyama
Journal:  Clin Exp Nephrol       Date:  2009-10-07       Impact factor: 2.801

10.  CD45RC isoform expression identifies functionally distinct T cell subsets differentially distributed between healthy individuals and AAV patients.

Authors:  Laurence Ordonez; Isabelle Bernard; Fatima-Ezzahra L'faqihi-Olive; Jan Willem Cohen Tervaert; Jan Damoiseaux; Abdelhadi Saoudi
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.